Blog · Evidence, in plain language

When the medicine works, but motivation does not come back.

Many patients in medication care describe the same puzzle. The voices are quieter, the fear has eased, and yet getting out of the house, starting a task, or enjoying anything still feels out of reach. Those are the negative symptoms of schizophrenia, and in October 2026 a treatment aimed at them, a prescription smartphone app, received FDA clearance for the first time. This post explains what was tested, what improved, and how much weight the result can carry.

By Karel Winner, DNP, PMHNP-BC · Published October 27, 2026

The symptoms medicines reach least well

Schizophrenia has two broad groups of symptoms. Positive symptoms add experiences: hallucinations, delusions, disorganized thinking. Antipsychotic medicines were built for those, and they are the symptoms medication treats best. Negative symptoms take experiences away: low motivation, called avolition; a reduced ability to feel or look forward to pleasure, called anhedonia; and pulling back from other people, called asociality. The trial paper states plainly that no FDA-approved medicine is specifically indicated for these symptoms, and that drug treatments aimed at the motivation and pleasure side of them have been ineffective. For many patients, negative symptoms, not positive ones, are what limit work, relationships, and daily life.

What was cleared, and what it actually is

The product is called Motivista, developed under the name CT-155. It is software, not a drug: a smartphone program a clinician prescribes, which the patient uses alongside ordinary outpatient care. The FDA clearance, announced on October 5, 2026, covers the treatment of negative symptoms of schizophrenia as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in adults whose positive symptoms are clinically stable. Adjunct is the key word. It is cleared to be added to medication care, never to replace it. The program delivers familiar therapy techniques in app form: setting goals that adapt to the person, working on defeatist beliefs, social skills practice, and skills for positive feelings and for distress. In the trial it was used for 16 weeks.

What the trial found

The CONVOKE trial randomized 457 adults at 66 sites in the United States. Their average age was 45.8 years, about 61 percent were men, everyone was on a stable antipsychotic regimen, and everyone had moderate to severe motivation and pleasure symptoms. Half received the therapeutic app and half received a control app with education material, and neither patients nor raters knew who had which. The main measure tracked motivation and pleasure symptoms over 16 weeks. Scores improved by 6.8 points in the app group and by 4.2 points in the control group, a difference of 2.6 points that was statistically significant. The researchers describe the size of that effect as small to moderate, and comparable to what psychosocial treatments and psychiatric medicines typically achieve. People used the app for almost 45 minutes a week, and about 70 percent were still active users near the end. Serious adverse events were uncommon in both groups, 1.3 percent against 2.2 percent, and none were judged related to the treatment.

How to read the headline number

The clearance announcement describes the same result as a 62 percent relative improvement. That figure is real arithmetic and easy to misread. It compares the extra 2.6 points of improvement against the control group's 4.2 points, so a modest gap on the symptom scale becomes a large sounding percentage. The control group improved too, which is common in psychiatric trials: regular contact, structure, and expectation all do some work. The honest reading is the researchers' own one. The app added a small to moderate benefit on top of a control app, on top of stable medication, for the specific symptoms it targets. That is a genuine first for this symptom group. It is not a transformation, and no single trial makes it one.

What the trial did not show

The gains were concentrated in the social and recreational parts of the measure, in analyses done after the main result. Change in work and school functioning was modest and about the same in both groups. Expressive symptoms, such as reduced facial expression or speech, did not improve significantly. Positive symptoms did not change, which the authors expected, since the program was not built for them. Patients' own rating of overall improvement was significantly better at week 8 but no longer significant at week 16. The trial also studied a selected group: people stable on medication for at least 12 weeks, who owned a smartphone with regular internet access, and who were not receiving psychotherapy. Results may not carry over to someone newly diagnosed, changing medicines, or without stable housing. One more fact belongs in plain view: the study was funded by Boehringer Ingelheim, the product was codeveloped by the two companies behind it, and several authors are their employees. That does not undo a blinded, randomized result, and it is a reason to want independent follow-up studies.

What this means at a medication visit

The practical change is narrow and useful. Negative symptoms can now be raised as a treatment target in their own right, with at least one option that has confirmatory trial evidence behind it. If low motivation, flat pleasure, or withdrawal are the symptoms that remain after positive symptoms settle, say so directly, and describe what they stop you doing. A prescriber cannot weigh an adjunct like this without knowing it is wanted, whether the stability conditions fit, and what else is on the medication list. What has not changed: the antipsychotic remains the foundation of schizophrenia treatment, and an app is an addition to that foundation, not an alternative to it.

Sources

This post is based on the sources below. The numbers quoted are the trial's own, taken from the published paper.

Pratap and colleagues, JAMA Network Open (2026): the CONVOKE trial, a phase 3, double-blind, randomized trial of the smartphone therapeutic CT-155 against a digital control app in 457 adults with negative symptoms of schizophrenia, run at 66 sites in the United States. JAMA Network Open.

ClinicalTrials.gov record NCT05838625: the registered CONVOKE study, its design, its eligibility rules, and its primary outcome measure. ClinicalTrials.gov record.

Click Therapeutics announcement, October 5, 2026: the FDA granted 510(k) clearance to Motivista (CT-155) for the treatment of negative symptoms of schizophrenia, as an adjunct to clinician-managed outpatient care including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms. FDA clearance announcement.

Please read this part

Nothing here is medical advice, and reading it does not create a treatment relationship. A trial describes averages across a selected group of patients. It cannot say whether a new treatment fits your diagnosis, your stability, or the medicines you already take. Do not stop or change an antipsychotic because an app has been cleared. If negative symptoms are part of your life, name them at your visit, in specific terms, and decide the next step with your prescriber.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.